K2M Group Holdings Inc (KTWO) reported quarterly earnings results on Monday, May-2-2016. The company reported $-0.25 earnings per share for the quarter, missing the analyst consensus estimate by $-0.02. Analysts had a consensus of $-0.23. The company posted revenue of $56.30 million in the period, compared to analysts expectations of $55.97 million. The company’s revenue was up 11.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.37 EPS.
Many Wall Street Analysts have commented on K2M Group Holdings Inc. K2M Group Holdings Inc was Initiated by JMP Securities to “Mkt Outperform” on Apr 8, 2016. Shares were Reiterated by Needham on Mar 4, 2016 to “Buy” and Lowered the Price Target to $ 21 from a previous price target of $25 .
K2M Group Holdings Inc opened for trading at $16.68 and hit $17.74 on the upside on Wednesday, eventually ending the session at $16.75, with a gain of 0.96% or 0.16 points. The heightened volatility saw the trading volume jump to 2,41,988 shares. Company has a market cap of $692 M.
In a different news, on Mar 7, 2016, Carlos A Ferrer (director) purchased 38,942 shares at $12.84 per share price. According to the SEC, on Nov 13, 2015, Gregory S Cole (Chief Financial Officer) sold 41,574 shares at $19.69 per share price. On Jun 24, 2015, John Philip Md Kostuik (Chief Medical Officer) sold 24,337 shares at $24.84 per share price, according to the Form-4 filing with the securities and exchange commission.
K2M Group Holdings Inc. (KTWO) is a global medical device company focused on designing developing and commercializing spine technologies and techniques. The Company’s spine products are used by spine surgeons to treat spinal pathologies such as deformity (primarily scoliosis) trauma and tumor. The Company is engaged in the design development and commercialization of a number of minimally invasive spine (MIS) products and products for patients suffering from degenerative spinal conditions. The Company’s products consist of implants disposables and instruments which are marketed and sold primarily to hospitals for use by spine surgeons. The Company’s technologies include MESA Rail 4D Deformity Cricket CAPRI SERENGETI RAVINE EVEREST and tifix. The Company offers products-based on its technologies for complex spine minimally invasive spine and degenerative spine. The Company is engaged in product development activities for the spine and MIS markets.